Stanford Cancer Institute
Translating Stanford discoveries into individualized cancer care
The Future of Cancer
The SCI is focused on pushing the limits of what we can do and what we know. The only way to really advance our knowledge is to push forward in laboratories, keep thinking about novel approaches, novel mechanisms. We cannot stand still.
National Cancer Institute Designation
The Stanford Cancer Institute has been designated a Comprehensive Cancer Center by the National Cancer Institute, a part of the National Institutes of Health and the world’s leading cancer research organization.
Designation as a Comprehensive Cancer Center signifies that the Stanford Cancer Institute maintains the highest level of scientific rigor, institutional support and coordination for the complete range of cancer-related research, including basic, translational, clinical and population-based science. The designation is recognition of the institute’s robust and integrated programs encompassing laboratory research, clinical care and community outreach and education.
The Institute’s mission is to support and coordinate the wide range of cancer-related activities — in basic, translational, clinical and population-based science — occurring at Stanford University, Stanford Health Care and Lucile Packard Children’s Hospital Stanford. Its over 450 members include scientists and physicians from a wide range of disciplines, all collaborating to translate research advances into improved cancer treatments.
Tumors called high-grade gliomas wire themselves into the healthy brain, receiving and interpreting electrical signals from normal neurons, a Stanford study has found.
Melissa Bondy has been appointed chair of the Department of Epidemiology and Population Health and associate director for population sciences at the Stanford Cancer Institute.
Weissman and Johns Hopkins’ Bert Vogelstein will share the 2019 Albany Medical Center Prize in Medicine and Biomedical Research for discoveries in stem cell and cancer biology.
Cancer Clinical Trials
Stanford Cancer Institute offers leading edge research and compassionate care with over 250 actively recruiting clinical trials, investigating a broad spectrum of new diagnostic, prevention and treatment strategies.